Relationship between gut hormones and glucose homeostasis after bariatric surgery

Diabetology & Metabolic Syndrome

Dan Linetzky Waitzberg²  Daniel Giannella-Neto¹  Raquel Susana Torrinhas²  Priscila Campos Sala² 

[1] University Nove de Julho, São Paulo, Brazil;Medical School, Department of Gastroenterology, Digestive Surgery Discipline (LIM 35), University of São Paulo, Av. Dr. Arnaldo, 455, Cerqueira César, CEP: 01246-903 São Paulo, Brazil

关键词: Glucose homeostasis;    Enteroendocrine cells;    Gut hormones;    Bariatric surgery;    Obesity;    Type 2 diabetes mellitus;   

Others  :  1115063
DOI  :  10.1186/1758-5996-6-87

 received in 2014-03-24, accepted in 2014-08-06,  发布年份 2014

【 摘 要 】

Type 2 diabetes mellitus (T2D) is emerging as a worldwide public health problem, and is mainly associated with an increased incidence of obesity. Bariatric surgery is currently considered the most effective treatment for severely obese patients. After bariatric surgery, T2D patients have shown a significant improvement in glycemic control, even before substantial weight loss and often discontinuation of medication for diabetes control. A central role for enteroendocrine cells from the epithelium of the gastrointestinal tract has been speculated in this postoperative phenomenon. These cells produce and secrete polypeptides - gut hormones - that are associated with regulating energy intake and glucose homeostasis through modulation of peripheral target organs, including the endocrine pancreas. This article reviews and discusses the biological actions of the gut hormones ghrelin, cholecystokinin, incretins, enteroglucagon, and Peptide YY, all of which were recently identified as potential candidates for mediators of glycemic control after bariatric surgery. In conclusion, current data reinforce the hypothesis that T2D reversion after bariatric surgery may be related to glycemic homeostasis developed by the intestine.

【 授权许可】

   
2014 Sala et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Lima-Costa MF, Peixoto SV, Firmo JO, Uchoa E: Validity of self-reported diabetes and its determinants: evidences from the Bambui study. Rev Saude Publica 2007, 41:947-953.
• [2]Lapolla A, Dalfra MG, Fedele D: Pregnancy complicated by type 2 diabetes: an emerging problem. Diabetes Res Clin Pract 2008, 80:2-7.
• [3]Holst JJ: Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol 2013, 13:983-988.
• [4]Flatt PR: Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone Gastric Inhibitory Polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? Diab Vasc Dis Res 2007, 4:151-153.
• [5]Bandeira F, Macedo G, Caldas G, Griz L, Faria MS: Endocrinologia e Diabetes Mellitus. São Paulo, Brazil: Medsi; 2003.
• [6]Osborn O, Olefsky JM: The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012, 18:3.
• [7]Mingrone G, Castagneto-Gissey L: Mechanisms of early improvement/ resolution of type 2 diabetes after bariatric surgery. Diabetes Metab 2009, 35:518-523.
• [8]Li B, Zhou X, Wo J, Zhou H: From gut changes to type 2 diabetes remission after gastric bypass surgeries. Front Med 2013, 7(2):191-200.
• [9]Karra E, Yousseif A, Batterham RL: Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metab 2010, 21:337-344.
• [10]Wilson JB, BaWJP MD: Durable remission of diabetes after bariatric surgery: What is the underlying pathway? Insulin 2010, 5:10.
• [11]American Diabetes Association: Standards of medical care in diabetes—2009. Diabetes Care 2009, 32:13-61.
• [12]ASMBS: American Society for Metabolic and Bariatric Surgery: Bariatric Surgery Procedures. 2014. [http://asmbs.org/patients/bariatric-surgery-procedures webcite]
• [13]Papamargaritis D, Le Roux CW, Sioka E, Koukoulis G, Tzovaras G, Zacharoulis D: Changes in hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 2013, 9:192-201.
• [14]Rubino F, Marescaux J: Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004, 239:1-11.
• [15]Paik KY, Kim W, Song KH, Kwon HS, Kim MK, Kim E: The preliminary clinical experience with laparoscopic duodenojejunal by pass for treatment of type 2 diabetes mellitus in non-morbidly obese patients: the 1-year result in a single institute. Surg Endosc 2012, 26(11):3287-3292.
• [16]Tsoli M, Chronaiou A, Kehagias I, Kalfarentzos F, Alexandrides TK: Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis 2013, 9:667-678.
• [17]Thomas S, Schauer P: Bariatric surgery and the gut hormone response. Nutr Clin Pract 2010, 25:175-182.
• [18]Scopinaro N, Gianetta E, Adami GF, Friedman D, Traverso E, Marinari GM, Cuneo S, Vitale B, Ballari F, Colombini M, Baschieri G, Bachi V: Biliopancreatic diversion for obesity at eighteen years. Surgery 1996, 119:261-268.
• [19]Hess DS, Hess DW: Biliopancreatic diversion with a duodenal switch. Obes Surg 1998, 8:267-282.
• [20]Wilson JB, Pories WJ: Durable remission of diabetes after bariatric surgery: What is the underlying pathway? Insulin 2010, 5:46-55.
• [21]Rubino F, Schauer PR, Kaplan LM, Cummings DE: Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010, 61:393-411.
• [22]Cummings DE: Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009, 33:33-40.
• [23]Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323.
• [24]Kashyap SR, Gatmaitan P, Brethauer S, Schauer P: Bariatric surgery for type 2 diabetes: weighing the impact for obese patients. Cleve Clin J Med 2010, 77:468-476.
• [25]Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
• [26]Rubino F: Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 2008, 3:290-296.
• [27]Scopinaro N, Marinari GM, Camerini GB, Papadia FS, Adami GF: Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005, 28:2406-2411.
• [28]Hall TC, Pellen MG, Sedman PC, Jain PK: Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg 2010, 20:1245-1250.
• [29]Sala PC, Torrinhas RS, Heymsfield SB, Waitzberg DL: Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction. Obes Surg 2012, 22:167-176.
• [30]Scheen AJ, De Flines J, De Roover A, Paquot N: Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab 2009, 35:537-543.
• [31]Cummings DE, Overduin J, Foster-Schubert KE: Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004, 89:2608-2615.
• [32]Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D: Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003, 238:467-484.
• [33]Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006, 244:741-749.
• [34]Knop FK: Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009, 52:2270-2276.
• [35]Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
• [36]Papamargaritis D, Miras AD, Le Roux CW: Influence of diabetes surgery on gut hormones and incretins. Nutr Hosp 2013, 28(2):95-103.
• [37]Mumphrey MB, Patterson LM, Zheng H, Berthoud HR: Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin expressing enteroendocrine cells in rats. Neurogastroenterol Motil 2013, 25:e70-e79.
• [38]Kellum JM, Kuemmerle JF, O’Dorisio TM, Rayford P, Martin D, Engle K, Wolf L, Sugerman HJ: Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990, 211:763-770.
• [39]Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S: Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in nondiabetic subjects. Obes Surg 2012, 22:1084-1096.
• [40]Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, Kern B, von Fluee M, Beglinger C: Metabolic and hormonal changes after laparoscopic Roux-en-Y Gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 2012, 22:740-748.
• [41]Karra E, Batterham RL: The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 2010, 25:120-128.
• [42]Murphy KG, Bloom SR: Gut hormones and the regulation of energy homeostasis. Nature 2006, 444(7121):854-859.
• [43]Drucker DJ: The role of gut hormones in glucose homeostasis. J Clin Invest 2007, 117:24-32.
• [44]Baynes KC, Dhillo WS, Bloom SR: Regulation of food intake by gastrointestinal hormones. Curr Opin Gastroenterol 2006, 22:626-631.
• [45]Naslund E, Kral JG: Impact of gastric bypass surgery on gut hormones and glucose homeostasis in type 2 diabetes. Diabetes 2006, 55:S92-S97.
• [46]Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Laferrere B: Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg 2009, 19:217-229.
• [47]Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346:1623-1630.
• [48]Vetter ML, Cardillo S, Rickels MR, Iqbal N: Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009, 150:94-103.
• [49]Peterli R, Borbély Y, Kern B, Gass M, Peters T, Thurnheer M, Schultes B, Laederach K, Bueter M, Schiesser M: Early of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS). A prospective randomized trial comparing laparoscopic sleeve gastrectomy and roux-en-Y gastric bypass. Ann Surg 2013, 258:690-695.
• [50]Zhang W, Zhu DQ, Qiu M: Hypothesis for resolution of diabetes after sleeve gastrectomy. Med Hypotheses 2012, 79:278-284.
• [51]Martins L, Fernández-Mallo D, Novelle MG, Vázquez MJ, Tena-Sempere M, Nogueiras R, López M, Diéguez C: Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin. PLoS One 2012, 7:10.
• [52]Halpern ZSC, Rodrigues MDB, Costa RF: Determinantes fisiológicos do controle do peso e apetite. Rev Psiquiatr Clín 2004, 31:150-153.
• [53]Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR: The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010, 57:359-372.
• [54]Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD: Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011, 7:683-690.
• [55]Buchan AM, Pederson RA, Koop I, Gourlay RH, Cleator IG: Morphological and functional alterations to a sub-group of regulatory peptides in human pancreas and intestine after jejuno-ileal bypass. Int J Obes Relat Metab Disord 1993, 17:109-113.
• [56]Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, Backman L: Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997, 21:387-392.
• [57]Griffen WO, Bivins BA, Bell RM: The decline and fall of jejunoileal bypass. Surg Gynecol Obstet 1983, 157:301-308.
• [58]Chacra AR: Efeito Fisiológico das Incretins. São Paulo, Brazil: Johns Hopkins Advanced Studies in Medicine; 2006.
• [59]SBD: Novas perspectivas para o tratamento do diabetes tipo 2: o tratamento do diabetes tipo 2: incretinomiméticos e inibidores da DPP-IV. Rev Bras Med 2007, 3:1-20.
• [60]Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
• [61]Reimann F: Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Int Dairy J 2010, 20:236-242.
• [62]Hare KJ: Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus. Dan Med Bull 2010, 57:4181.
• [63]Vilsboll T: On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan Med Bull 2004, 51:364-370.
• [64]Ranganath LR: Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol 2008, 61:401-409.
• [65]Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ, Ikramuddin S: Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res 2007, 141:31-39.
• [66]Vahl TP, Paty BW, Fuller BD, Prigeon RL, D’Alessio DA: Effects of GLP-1 (7–36) NH2, GLP (7–37), and GLP-1 (9–36) NH2 on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans. J Clin Endocrinol Metab 2003, 88:1772-1779.
• [67]De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunol Today 1999, 20:367-375.
• [68]Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B: Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007, 30:1709-1716.
• [69]Jorde R, Burhol PG, Johnson JA: The effect of jejunoileal bypass on postprandial release of plasma gastric inhibitory polypeptide (GIP). Scand J Gastroenterol 1981, 16:313-319.
• [70]Sirinek KR, O'Dorisio TM, Hill D, McFee AS: Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery 1986, 100:781-787.
• [71]Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G: Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006, 55:2025-2031.
• [72]Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B: Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:2479-2485.
• [73]Laferrere B: Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009, 35:513-517.
• [74]Shak JR, Roper J, Perez-Perez GI, Tseng CH, Francois F, Gamagaris Z, Patterson C, Weinshel E, Fielding GA, Ren C, Blaser MJ: The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg 2008, 18:1089-1096.
• [75]Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ: Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007, 3:597-601.
• [76]Sinclair EM, Drucker DJ: Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology (Bethesda) 2005, 20:357-365.
• [77]Holst JJ: Enteroglucagon. Annu Rev Physiol 1997, 59:257-271.
• [78]Kahn CR, Weir GC, King GL: Jacobson AM. Smith RJ. Joslin - Diabetes Melito. Artmed: Moses AC; 2009.
• [79]Laferrere B, Swerdlow N, Bawa B, Arias S, Bose M, Olivan B, Teixeira J, McGinty J, Rother KI: Rise of oxyntomodulin in respone to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:4072-4076.
• [80]Troke RC, Tan TM, Bloom SR: The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis 2014, 5(1):4-14.
• [81]Yamada T, Alpers DH, Laine L, Owyang C: Powell DW. Textbook of Gastroenterology. Ed: Lippincott Williams & Wilkins; 1999.
• [82]Ballantyne GH, Peptide YY: (1–36) and Peptide YY (3–36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery: Part I: Distribution, Release and Action appeared in the last issue. Obes Surg 2006, 16:795-803.
• [83]Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lönroth H, Fändriks L, Ghatei MA, Bloom SR, Olbers T: Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007, 246:780-785.
• [84]Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Delgado S, Casamitjana R, Vidal J: Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006, 91:1735-1740.
• [85]Andreelli F, Amouyal C, Magnan C, Mithieux G: What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes Metab 2009, 35:499-507.
• [86]van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl H: PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 2004, 53:1949-1952.
• [87]Pimentel GD, Micheletti TO, Pace F, Rosa JC, Santos RVT, Lira FS: Gut-central nervous system axis is a target for nutritional therapies. Nutr J 2012, 10:11-22.
• [88]Mechanick JI, Youdim A, Jones DB: Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. AACE/TOS/ASMBS Guidelines. Surg Obes Relat Dis 2013, 9:159-191.
• [89]Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256.e5.
• [90]Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR, STAMPEDE Investigators: Bariatric surgery versus intensive medical therapy for diabetes — 3-year outcomes. N Engl J Med 2014, 370:21.
• [91]Varela JE: Bariatric surgery: a cure for diabetes? Curr Opin Clin Nutr Metab Care 2011, 14:396-401.
• [92]Chikunguwo SM, Wolfe LG, Dodson P, Meador JG, Baugh N, Clore JN, Kellum JM, Maher JW: Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010, 6(3):254-259.
• [93]DiGiorgi M, Rosen DJ, Choi JJ, Milone L, Schrope B, Olivero-Rivera L, Restuccia N, Yuen S, Fisk M, Inabnet WB, Bessler M: Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010, 6(3):249-253.
• [94]Abbatini F, Rizzelo M, Casella G, Alessandri G, Capoccia D, Leonetti F, Basso N: Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc 2010, 24:1005-1010.
• [95]Chang S-H, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA: The effectiveness and risks of bariatric surgery. An updated systematic review and meta-analysis, 2003–2013. JAMA Surg 2014, 149(3):275-287.
• [96]Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC: Long-term weight regain aftar gastric bypass: a 5-year prospective study. Obes Surg 2008, 18:648-651.